Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.

Authors: Voso, M T  Fabiani, E  Piciocchi, A  Matteucci, C  Brandimarte, L  Finelli, C  Pogliani, E  Angelucci, E  Fioritoni, G  Musto, P  Greco, M  Criscuolo, M  Fianchi, L  Vignetti, M  Santini, V  Hohaus, S  Mecucci, C  Leone, G 
Citation: Voso MT, etal., Leukemia. 2011 Dec;25(12):1910-3. doi: 10.1038/leu.2011.170. Epub 2011 Jul 15.
Pubmed: (View Article at PubMed) PMID:21760590
DOI: Full-text: DOI:10.1038/leu.2011.170

Abstract for this paper unavailable


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 14392809
Created: 2019-03-04
Species: All species
Last Modified: 2019-03-04
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.